Long-term treatment outcome for nonprioritized cytogenetic groups
Cytogenetic group . | No. of patients . | No. of CRs . | 5-y CIR (SE) . | P5-150 . | Median OS, y . | 5-y OS (95% CI) . | P5-150 . |
---|---|---|---|---|---|---|---|
Normal | 582 | 395 | 0.66 (0.02) | NA | 1.3 | 24 (20-27) | NA |
del(9q) | 33 | 31 | 0.58 (0.09) | .41 | >4.6 | 55 (38-71) | <.001 |
Sole del(9q) | 11 | 10 | 0.50 (0.17) | .28 | >4.6 | 55 (28-79) | .02 |
t(8;21) | 81 | 74 | 0.47 (0.05) | .009 | 5.1 | 52 (40-63) | <.001 |
inv(16) or t(16;16) | 96 | 82 | 0.55 (0.05) | .02 | 7.9 | 57 (47-67) | <.001 |
−X | 18 | 15 | 0.53 (0.14) | .41 | 1.3 | 44 (25-66) | .08 |
Balanced abn(11q23) | 54 | 40 | 0.75 (0.07) | .008 | 0.8 | 20 (11-34) | .14 |
t(9;11) | 27 | 23 | 0.57 (0.11) | .80 | 1.1 | 41 (24-60) | .25 |
t(11;v)5-151 | 13 | 9 | 1.00 (0.11) | <.001 | 0.7 | 0 | .02 |
t(6;11) | 8 | 5 | 1.00 (0.20) | .002 | 0.6 | 0 | .003 |
t(11;19)(q23;p13.1) | 6 | 3 | ND | ND | 0.6 | 0 | .03 |
del(13q) | 9 | 6 | 0.83 (0.20) | .12 | 0.7 | 11 (3-33) | .16 |
−Y | 58 | 38 | 0.58 (0.08) | .40 | 1.2 | 27 (17-41) | .96 |
Sole −Y | 14 | 10 | 0.80 (0.15) | .47 | 1.7 | 29 (13-52) | .99 |
+22 | 31 | 20 | 0.12 (0.31) | .31 | 1.2 | 32 (19-50) | .66 |
+8 | 123 | 71 | 0.69 (0.06) | .83 | 1.0 | 20 (14-29) | .12 |
+21 | 28 | 16 | 0.88 (0.10) | .002 | 1.0 | 10 (3-25) | .17 |
+13 | 29 | 16 | 0.75 (0.12) | .52 | 1.1 | 7 (2-18) | .04 |
del(11q) | 12 | 6 | 0.67 (0.23) | .90 | 0.6 | 17 (6-39) | .27 |
+4 | 14 | 7 | 1.00 (0.14) | .10 | 0.9 | 14 (5-35) | .09 |
+11 | 20 | 9 | 0.89 (0.14) | .28 | 0.9 | 5 (1-17) | .03 |
+14 | 12 | 5 | 0.40 (0.25) | .30 | 0.5 | 25 (10-49) | .72 |
−7/7q− | 95 | 41 | 0.83 (0.06) | <.001 | 0.5 | 7 (4-14) | <.001 |
−7 | 47 | 20 | 0.90 (0.09) | <.001 | 0.5 | 0 | <.001 |
Loss of 7q | 29 | 10 | 0.70 (0.16) | .30 | 0.4 | 10 (4-24) | <.001 |
del(7q) | 19 | 11 | 0.82 (0.13) | .16 | 0.9 | 21 (9-41) | .16 |
−20/20q− | 39 | 15 | 0.93 (0.15) | .003 | 0.3 | 5 (2-14) | <.001 |
del(20q) | 16 | 8 | 0.88 (0.28) | .49 | 0.3 | 13 (4-31) | .01 |
−20 | 15 | 5 | 1.00 (0.20) | <.001 | 0.3 | 0 | <.001 |
Loss of 20q | 8 | 2 | ND | ND | 0.1 | 0 | <.001 |
t(6;9) | 8 | 3 | ND | ND | 0.9 | 0 | .03 |
abn(12p) | 33 | 11 | 0.82 (0.13) | <.001 | 0.3 | 3 (1-10) | <.001 |
Unbalanced abn(12p) | 25 | 9 | 0.78 (0.16) | .009 | 0.3 | 4 (1-13) | <.001 |
Balanced abn(12p) | 8 | 2 | ND | ND | 0.2 | 0 | .01 |
−5/5q− | 86 | 27 | 0.93 (0.06) | <.001 | 0.3 | 6 (3-12) | <.001 |
del(5q) | 42 | 11 | 0.82 (0.13) | .002 | 0.3 | 5 (2-13) | <.001 |
−5 | 26 | 12 | 1.00 (0.08) | .01 | 0.2 | 4 (1-13) | <.001 |
Loss of 5q | 18 | 4 | ND | ND | 0.2 | 11 (4-28) | <.001 |
−17/17p− | 62 | 19 | 1.00 (0.05) | <.001 | 0.2 | 2 (1-6) | <.001 |
−17 | 32 | 9 | 1.00 (0.11) | .002 | 0.1 | 3 (1-11) | <.001 |
Loss of 17p | 30 | 10 | 1.00 (0.10) | <.001 | 0.3 | 0 | <.001 |
−18 | 30 | 8 | 1.00 (0.13) | <.001 | 0.2 | 0 | <.001 |
inv(3) or t(3;3) | 12 | 2 | ND | ND | 0.2 | 0 | <.001 |
Cytogenetic group . | No. of patients . | No. of CRs . | 5-y CIR (SE) . | P5-150 . | Median OS, y . | 5-y OS (95% CI) . | P5-150 . |
---|---|---|---|---|---|---|---|
Normal | 582 | 395 | 0.66 (0.02) | NA | 1.3 | 24 (20-27) | NA |
del(9q) | 33 | 31 | 0.58 (0.09) | .41 | >4.6 | 55 (38-71) | <.001 |
Sole del(9q) | 11 | 10 | 0.50 (0.17) | .28 | >4.6 | 55 (28-79) | .02 |
t(8;21) | 81 | 74 | 0.47 (0.05) | .009 | 5.1 | 52 (40-63) | <.001 |
inv(16) or t(16;16) | 96 | 82 | 0.55 (0.05) | .02 | 7.9 | 57 (47-67) | <.001 |
−X | 18 | 15 | 0.53 (0.14) | .41 | 1.3 | 44 (25-66) | .08 |
Balanced abn(11q23) | 54 | 40 | 0.75 (0.07) | .008 | 0.8 | 20 (11-34) | .14 |
t(9;11) | 27 | 23 | 0.57 (0.11) | .80 | 1.1 | 41 (24-60) | .25 |
t(11;v)5-151 | 13 | 9 | 1.00 (0.11) | <.001 | 0.7 | 0 | .02 |
t(6;11) | 8 | 5 | 1.00 (0.20) | .002 | 0.6 | 0 | .003 |
t(11;19)(q23;p13.1) | 6 | 3 | ND | ND | 0.6 | 0 | .03 |
del(13q) | 9 | 6 | 0.83 (0.20) | .12 | 0.7 | 11 (3-33) | .16 |
−Y | 58 | 38 | 0.58 (0.08) | .40 | 1.2 | 27 (17-41) | .96 |
Sole −Y | 14 | 10 | 0.80 (0.15) | .47 | 1.7 | 29 (13-52) | .99 |
+22 | 31 | 20 | 0.12 (0.31) | .31 | 1.2 | 32 (19-50) | .66 |
+8 | 123 | 71 | 0.69 (0.06) | .83 | 1.0 | 20 (14-29) | .12 |
+21 | 28 | 16 | 0.88 (0.10) | .002 | 1.0 | 10 (3-25) | .17 |
+13 | 29 | 16 | 0.75 (0.12) | .52 | 1.1 | 7 (2-18) | .04 |
del(11q) | 12 | 6 | 0.67 (0.23) | .90 | 0.6 | 17 (6-39) | .27 |
+4 | 14 | 7 | 1.00 (0.14) | .10 | 0.9 | 14 (5-35) | .09 |
+11 | 20 | 9 | 0.89 (0.14) | .28 | 0.9 | 5 (1-17) | .03 |
+14 | 12 | 5 | 0.40 (0.25) | .30 | 0.5 | 25 (10-49) | .72 |
−7/7q− | 95 | 41 | 0.83 (0.06) | <.001 | 0.5 | 7 (4-14) | <.001 |
−7 | 47 | 20 | 0.90 (0.09) | <.001 | 0.5 | 0 | <.001 |
Loss of 7q | 29 | 10 | 0.70 (0.16) | .30 | 0.4 | 10 (4-24) | <.001 |
del(7q) | 19 | 11 | 0.82 (0.13) | .16 | 0.9 | 21 (9-41) | .16 |
−20/20q− | 39 | 15 | 0.93 (0.15) | .003 | 0.3 | 5 (2-14) | <.001 |
del(20q) | 16 | 8 | 0.88 (0.28) | .49 | 0.3 | 13 (4-31) | .01 |
−20 | 15 | 5 | 1.00 (0.20) | <.001 | 0.3 | 0 | <.001 |
Loss of 20q | 8 | 2 | ND | ND | 0.1 | 0 | <.001 |
t(6;9) | 8 | 3 | ND | ND | 0.9 | 0 | .03 |
abn(12p) | 33 | 11 | 0.82 (0.13) | <.001 | 0.3 | 3 (1-10) | <.001 |
Unbalanced abn(12p) | 25 | 9 | 0.78 (0.16) | .009 | 0.3 | 4 (1-13) | <.001 |
Balanced abn(12p) | 8 | 2 | ND | ND | 0.2 | 0 | .01 |
−5/5q− | 86 | 27 | 0.93 (0.06) | <.001 | 0.3 | 6 (3-12) | <.001 |
del(5q) | 42 | 11 | 0.82 (0.13) | .002 | 0.3 | 5 (2-13) | <.001 |
−5 | 26 | 12 | 1.00 (0.08) | .01 | 0.2 | 4 (1-13) | <.001 |
Loss of 5q | 18 | 4 | ND | ND | 0.2 | 11 (4-28) | <.001 |
−17/17p− | 62 | 19 | 1.00 (0.05) | <.001 | 0.2 | 2 (1-6) | <.001 |
−17 | 32 | 9 | 1.00 (0.11) | .002 | 0.1 | 3 (1-11) | <.001 |
Loss of 17p | 30 | 10 | 1.00 (0.10) | <.001 | 0.3 | 0 | <.001 |
−18 | 30 | 8 | 1.00 (0.13) | <.001 | 0.2 | 0 | <.001 |
inv(3) or t(3;3) | 12 | 2 | ND | ND | 0.2 | 0 | <.001 |
CR indicates complete remission; CIR, cumulative incidence of relapse; OS, overall survival; CI, confidence interval; NA, not applicable; and ND, not done.
For comparison of a given abnormality with normal cytogenetics.
v denotes various chromosomes (other than chromosomes 6, 9, and 19 with a break at p13.1) participating in translocations with chromosome 11 at band q23.